Cargando…

Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection

BACKGROUND: The microbial community affects the occurrence, development, metastasis and treatment response of cancers. But the detailed role and characteristics of lung microbiota (LM) in non-small cell lung cancer (NSCLC) are not fully known. For NSCLC associated microbiota analysis, it is valuable...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Miao, Zhang, Yan, Han, Yaguang, Zhao, Xin, Sun, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904948/
https://www.ncbi.nlm.nih.gov/pubmed/35281416
http://dx.doi.org/10.21037/tcr-22-92
_version_ 1784665072839163904
author Zhang, Miao
Zhang, Yan
Han, Yaguang
Zhao, Xin
Sun, Yi
author_facet Zhang, Miao
Zhang, Yan
Han, Yaguang
Zhao, Xin
Sun, Yi
author_sort Zhang, Miao
collection PubMed
description BACKGROUND: The microbial community affects the occurrence, development, metastasis and treatment response of cancers. But the detailed role and characteristics of lung microbiota (LM) in non-small cell lung cancer (NSCLC) are not fully known. For NSCLC associated microbiota analysis, it is valuable to combine multiple levels of detection, e.g., tumor, blood plasma, and bronchoalveolar fluid (BALF), but not single tissues. METHODS: This study collected above three sample types from NSCLC patients free from lung infection and aimed to describe their LM features using sequencing techniques. All patients diagnosed at the Department of Oncology in Shijiazhuang People’s Hospital with stage III or IV NSCLC from May 2019 to April 2020 were enrolled. All 37 pieces of tumor tissues and 6 blood samples were sent for pathogen targeted sequencing; for the BALF samples, 4 were used for pathogen targeted sequencing and 2 were sent for 16S ribosomal DNA (rDNA) sequencing. RESULTS: We detected 49 pathogenic microorganisms (PMs) in the 37 tumor samples, 28 PMs in the 4 BALF samples, and 14 PMs in the 6 plasma samples. Overall, there were 5 common PMs in 3 types of samples. Between the tumor and BALF samples, there were another 11 common elements. In the 5 tumor-plasma pairs, the presence of a specific PM in blood was not necessarily consistent with that in the tumor. In the tumor-BALF pairs, the PM diversity was dramatically higher in the BALF than in the tumor. The PMs detected in the BALF could largely cover the PMs in the tumor. In the BALF 16S rDNA sequencing, there were 82 common operational taxonomic units (OTUs), and the microbiota in the BALF of advanced NSCLC patients exhibited some similarity. CONCLUSIONS: This study showed the unique features of LM. The amount of intra-tumoral PMs was not necessarily consistent with that in the blood, but there was an obvious correlation between the intra-tumoral microbiota and that in the BALF. It is convenient and non-invasive to obtain BALF. Detection of LM classification and abundance in the BALF may help evaluate the severity of NSCLC.
format Online
Article
Text
id pubmed-8904948
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-89049482022-03-10 Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection Zhang, Miao Zhang, Yan Han, Yaguang Zhao, Xin Sun, Yi Transl Cancer Res Original Article BACKGROUND: The microbial community affects the occurrence, development, metastasis and treatment response of cancers. But the detailed role and characteristics of lung microbiota (LM) in non-small cell lung cancer (NSCLC) are not fully known. For NSCLC associated microbiota analysis, it is valuable to combine multiple levels of detection, e.g., tumor, blood plasma, and bronchoalveolar fluid (BALF), but not single tissues. METHODS: This study collected above three sample types from NSCLC patients free from lung infection and aimed to describe their LM features using sequencing techniques. All patients diagnosed at the Department of Oncology in Shijiazhuang People’s Hospital with stage III or IV NSCLC from May 2019 to April 2020 were enrolled. All 37 pieces of tumor tissues and 6 blood samples were sent for pathogen targeted sequencing; for the BALF samples, 4 were used for pathogen targeted sequencing and 2 were sent for 16S ribosomal DNA (rDNA) sequencing. RESULTS: We detected 49 pathogenic microorganisms (PMs) in the 37 tumor samples, 28 PMs in the 4 BALF samples, and 14 PMs in the 6 plasma samples. Overall, there were 5 common PMs in 3 types of samples. Between the tumor and BALF samples, there were another 11 common elements. In the 5 tumor-plasma pairs, the presence of a specific PM in blood was not necessarily consistent with that in the tumor. In the tumor-BALF pairs, the PM diversity was dramatically higher in the BALF than in the tumor. The PMs detected in the BALF could largely cover the PMs in the tumor. In the BALF 16S rDNA sequencing, there were 82 common operational taxonomic units (OTUs), and the microbiota in the BALF of advanced NSCLC patients exhibited some similarity. CONCLUSIONS: This study showed the unique features of LM. The amount of intra-tumoral PMs was not necessarily consistent with that in the blood, but there was an obvious correlation between the intra-tumoral microbiota and that in the BALF. It is convenient and non-invasive to obtain BALF. Detection of LM classification and abundance in the BALF may help evaluate the severity of NSCLC. AME Publishing Company 2022-02 /pmc/articles/PMC8904948/ /pubmed/35281416 http://dx.doi.org/10.21037/tcr-22-92 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Zhang, Miao
Zhang, Yan
Han, Yaguang
Zhao, Xin
Sun, Yi
Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title_full Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title_fullStr Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title_full_unstemmed Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title_short Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection
title_sort lung microbiota features of stage iii and iv non-small cell lung cancer patients without lung infection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904948/
https://www.ncbi.nlm.nih.gov/pubmed/35281416
http://dx.doi.org/10.21037/tcr-22-92
work_keys_str_mv AT zhangmiao lungmicrobiotafeaturesofstageiiiandivnonsmallcelllungcancerpatientswithoutlunginfection
AT zhangyan lungmicrobiotafeaturesofstageiiiandivnonsmallcelllungcancerpatientswithoutlunginfection
AT hanyaguang lungmicrobiotafeaturesofstageiiiandivnonsmallcelllungcancerpatientswithoutlunginfection
AT zhaoxin lungmicrobiotafeaturesofstageiiiandivnonsmallcelllungcancerpatientswithoutlunginfection
AT sunyi lungmicrobiotafeaturesofstageiiiandivnonsmallcelllungcancerpatientswithoutlunginfection